Terms: = Gastric cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
137 results:
1. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
[TBL] [Abstract] [Full Text] [Related]
2. Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in gastric Carcinogenesis.
Won Y; Jang B; Lee SH; Reyzer ML; Presentation KS; Kim H; Caldwell B; Zhang C; Lee HS; Lee C; Trinh VQ; Tan MCB; Kim K; Caprioli RM; Choi E
Gastroenterology; 2024 May; 166(5):772-786.e14. PubMed ID: 38272100
[TBL] [Abstract] [Full Text] [Related]
3. Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer.
Zhang Z; Huang J; Li Y; Yan H; Xie J; Wang J; Zhao B
Aging (Albany NY); 2024 Jan; 16(1):948-963. PubMed ID: 38224334
[TBL] [Abstract] [Full Text] [Related]
4. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
5. Characteristic Mutational Damages in gastric and Colorectal Adenocarcinomas.
Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
[TBL] [Abstract] [Full Text] [Related]
6. Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in gastric Carcinogenesis.
Kim H; Jang B; Zhang C; Caldwell B; Park DJ; Kong SH; Lee HJ; Yang HK; Goldenring JR; Choi E
Gastroenterology; 2024 Jan; 166(1):117-131. PubMed ID: 37802423
[TBL] [Abstract] [Full Text] [Related]
7. Bacterial lipopolysaccharide related genes signature as potential biomarker for prognosis and immune treatment in gastric cancer.
Yuan T; Zhang S; He S; Ma Y; Chen J; Gu J
Sci Rep; 2023 Sep; 13(1):15916. PubMed ID: 37741901
[TBL] [Abstract] [Full Text] [Related]
8. DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells.
Chen Z; Zhang L; Yang Y; Liu H; Kang X; Nie Y; Fan D
Epigenetics; 2023 Dec; 18(1):2254976. PubMed ID: 37691391
[TBL] [Abstract] [Full Text] [Related]
9. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic gastric cancer by Liquid Biopsy.
Jung SH; Lee CK; Kwon WS; Yun S; Jung M; Kim HS; Chung HC; Chung YJ; Rha SY
Yonsei Med J; 2023 Sep; 64(9):531-540. PubMed ID: 37634629
[TBL] [Abstract] [Full Text] [Related]
10. Exploring the molecular mechanism of glycyrrhetinic acid in the treatment of gastric cancer based on network pharmacology and experimental validation.
Li X; Du Y; Huang S; Yang Y; Lu D; Zhang J; Chen Y; Zhang L; Nan Y; Yuan L
Aging (Albany NY); 2023 May; 15(9):3839-3856. PubMed ID: 37171392
[TBL] [Abstract] [Full Text] [Related]
11. [Landscape of kras, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable gastric cancer].
Danishevich AM; Pospehova NI; Stroganova AM; Golovina DA; Nikulin MP; Kalinin AE; Nikolaev SE; Stilidi IS; Lyubchenko LN
Mol Biol (Mosk); 2023; 57(1):71-84. PubMed ID: 36976740
[TBL] [Abstract] [Full Text] [Related]
12. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
13. The clinical impact of testing for biomarkers in gastric cancer patients: a real-world cohort.
van der Sluis K; van Sandick JW; van Dieren JM; Vollebergh MA; Grootscholten C; van den Berg JG; Snaebjornsson P; Hartemink KJ; Veenhof AAFA; Chalabi M; Kodach LL
Histopathology; 2023 May; 82(6):826-836. PubMed ID: 36694277
[TBL] [Abstract] [Full Text] [Related]
14. The Impact of Poorly Differentiated Histology on Immunotherapy in Advanced Gastrointestinal cancers.
Draper A; Jung EH; Cao Y; Atallah RP; Switchenko J; Kane S; Guadagno J; Jones AT; Brutcher E; Alese OB
Oncology; 2023; 101(4):213-223. PubMed ID: 36626879
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract] [Full Text] [Related]
16. Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis.
Xu T; Wang X; Xin Y; Wang Z; Gong J; Zhang X; Li Y; Ji C; Sun Y; Zhao F; Huang D; Bai Y; Li J; Shen L
Cancer Res Treat; 2023 Apr; 55(2):626-635. PubMed ID: 36550683
[TBL] [Abstract] [Full Text] [Related]
17. SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in kras-mutant gastric cancer through the suppression of KSR1 activity.
Zheng W; Yang Z; Song P; Sun Y; Liu P; Yue L; Lv K; Wang X; Shen Y; Si J; Zhang X; Ke Y; Cheng H; Hu W
Cancer Lett; 2023 Feb; 555():216029. PubMed ID: 36493900
[TBL] [Abstract] [Full Text] [Related]
18. HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced gastric cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.
Pietrantonio F; Manca P; Bellomo SE; Corso S; Raimondi A; Berrino E; Morano F; Migliore C; Niger M; Castagnoli L; Pupa SM; Marchiò C; Di Bartolomeo M; Restuccia E; Lambertini C; Tabernero J; Giordano S
Clin Cancer Res; 2023 Feb; 29(3):571-580. PubMed ID: 36413222
[TBL] [Abstract] [Full Text] [Related]
19. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
[TBL] [Abstract] [Full Text] [Related]
20. Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer.
Seidlitz T; Schmäche T; Garcίa F; Lee JH; Qin N; Kochall S; Fohgrub J; Pauck D; Rothe A; Koo BK; Weitz J; Remke M; Muñoz J; Stange DE
EMBO Mol Med; 2022 Oct; 14(10):e15705. PubMed ID: 35993110
[TBL] [Abstract] [Full Text] [Related]
[Next]
